In a phase 2 trial of 65 people with Fuchs endothelial corneal dystrophy after Descemet stripping only, ripasudil four times daily for 12 weeks gave higher central endothelial cell density at 12 weeks than placebo (531 vs 228 cells/mm2); adverse events were mild.
RCTn = 65
Colby et al. Descemet Stripping Only in Fuchs Endothelial Corneal Dystrophy: Results of a Randomized Clinical Trial of Topical Ripasudil and Directions for Future Innovation